...
首页> 外文期刊>Leukemia and lymphoma >Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria.
【24h】

Stem cell factor-induced bone marrow mast cell hyperplasia mimicking systemic mastocytosis (SM): histopathologic and morphologic evaluation with special reference to recently established SM-criteria.

机译:干细胞因子诱导的模拟系统性肥大细胞增生症(SM)的骨髓肥大细胞增生:组织病理学和形态学评估,特别参考最近建立的SM标准。

获取原文
获取原文并翻译 | 示例
           

摘要

Although systemic mastocytosis (SM) is a well-defined hematologic neoplasm, it is sometimes difficult to discriminate between SM and a reactive mast cell (MC) hyperplasia. We describe a patient with aplastic anemia who was treated with recombinant stem cell factor (SCF). In response to SCF, the patient showed transient hematologic improvement and developed a marked increase in MC as well as a transient increase in serum tryptase. Histologic and immunohistochemical examination revealed a huge increase in MC in the bone marrow with focal infiltrates similar to SM. However, most of the SM-criteria were not met: First, MC showed normal cytomorphological characteristics without significant atypias (no cytoplasmic extensions, no oval nuclei, no hypogranulated cytoplasm). Furthermore, bone marrow MC were CD2- and CD25-negative and did not exhibit the C-KIT 2468 A-->T mutation (Asp-816-Val). After discontinuation of SCF the MC hyperplasia resolved confirming its reactive nature. Based on our case and similar cases mimicking mastocytosis, it seems of importance to apply recently established SM criteria in order to discriminate between reactive MC hyperplasia and true mastocytosis with certainty.
机译:尽管全身性肥大细胞增多症(SM)是定义明确的血液肿瘤,但有时很难区分SM和反应性肥大细胞(MC)增生。我们描述了患有再生障碍性贫血的患者,该患者接受了重组干细胞因子(SCF)的治疗。对SCF的反应是,患者表现出短暂的血液学改善,MC明显升高,血清类胰蛋白酶也出现短暂升高。组织学和免疫组织化学检查显示,骨髓中MC大量增加,局部浸润类似于SM。但是,大多数SM标准没有得到满足:首先,MC表现出正常的细胞形态学特征,没有明显的异型性(无细胞质延伸,没有卵形核,没有低粒状细胞质)。此外,骨髓MC为CD2和CD25阴性,并且不表现出C-KIT 2468 A→T突变(Asp-816-Val)。终止SCF后,MC增生消失,证实了其反应性。根据我们的案例和类似的模拟肥大细胞增多症的病例,应用最新建立的SM标准似乎很重要,以便能够确定性地区分反应性MC增生和真正的肥大细胞增多症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号